Comparison 2.
Rifampicin plus INH versus INH
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Active TB: INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 328 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.08 [0.65, 1.79] |
| 2 Drug‐resistant TB | 1 | 80 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.36 [0.08, 1.65] |
| 2.1 INH resistant TB: INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 40 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.36 [0.08, 1.65] |
| 2.2 Rifampicin resistant TB: (INH plus rifampicin 3 months versus INH 6 months in adults with silicosis) | 1 | 40 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 3 Adherence | 2 | 524 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.07 [0.98, 1.17] |
| 3.1 INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 328 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.91, 1.17] |
| 3.2 INH plus rifampicin 3 months versus INH 9 months (in adults) | 1 | 196 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [1.00, 1.27] |
| 4 Serious adverse events: INH plus rifampicin 3 months versus INH 9 months (in adults) | 1 | 196 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.78 [0.30, 2.01] |
| 5 Treatment‐limiting adverse events | 2 | 536 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.74, 1.82] |
| 5.1 INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 340 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.12 [0.67, 1.87] |
| 5.2 INH plus rifampicin 3 months versus INH 9 months (in adults) | 1 | 196 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.29 [0.50, 3.32] |
| 6 Hepatotoxicity | 2 | 536 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.43, 1.81] |
| 6.1 INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 340 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.89 [0.30, 2.59] |
| 6.2 INH plus rifampicin 3 months versus INH 9 months (in adults) | 1 | 196 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.33, 2.32] |
| 7 Gastrointestinal intolerance | 2 | 510 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.34 [0.80, 2.27] |
| 7.1 INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 314 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.66 [0.78, 3.55] |
| 7.2 INH plus rifampicin 3 months versus INH 9 months (in adults) | 1 | 196 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.08 [0.52, 2.25] |
| 8 Any adverse event: INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis) | 1 | 314 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.82, 1.65] |